Common types of CLD in the United States are increasing:
Non-alcoholic fatty liver disease (NAFLD) and resulting non-alcoholic steatohepatitis (NASH) are forecasted to increase 21% and 63%, respectively, between 2015 and 2030 due to high rates of diabetes and obesity.*3
Decompensated cirrhosis may increase 168% by 2030, while hepatocellular carcinoma will increase by 137%.*3
As the prevalence of cirrhosis rises, it is expected that cirrhosis complications, including hepatic encephalopathy (HE), will also rise.
The prevalence of minimal or covert HE (CHE) occurs in as many as 50% of patients with CLD, so guidelines recommend every CLD patient be screened.4
Overt HE (OHE) is estimated to occur in up to 30% to 40% of patients with cirrhosis.4
Screening for CHE is important because it can prognosticate OHE development, indicate poor quality of life, and help identify patients and caregivers who may need to be counseled about the disease.4
HE affects the patient, the patient’s family, and everyone the patient comes in contact with. HE affects the patient’s ability to work and drive, and increases health care costs. It is important to recognize and treat HE to improve these conditions.5
LIVERHEALTHNOW has resources to support you as you screen CLD patients for HE, with tools for providers and companion patient and caregiver tools to educate patients through screening and diagnosis of HE.
You can add your organization logo to the resources and create favorite links of the tools.